Wegovy, Saxenda and Zepbound are approved for weight loss in the following individuals: Adults with an initial BMI of 30, defined as obesity Adults with an initial BMI of 27, defined as overweight, with at least one weight-related comorbid condition Weight-related comorbid conditions include high blood pressure, cardiovascular disease (such as coronary artery disease, heart attack or heart failure), high cholesterol, obstructive sleep apnea, type 2 diabetes, fatty liver, GERD/acid reflux, osteoarthritis, urinary incontinence, etc
Structured nutrition and physical activity
190 , 400411 (2020) M
It has a significantly longer half-life than GLP-1 and could be significant in the treatment of type 2 diabetes mellitus and NAFLD
Here's where it gets interesting: some of the mechanisms tirzepatide corrects (insulin resistance, chronic inflammation, leptin excess) are the very mechanisms driving obesity-related low supply